Bhaskar Anand
Known title: Chief Accounting OfficerCIK: 0001890784
Associated companies
Transaction History
| SMMT | ▲ Buy | Grant | 26,680 | $500K | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 22,026 | $500K | 9/11/2024 | View on chart |
| SMMT | ▲ Buy | Grant | 26,680 | $500K | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 22,026 | $500K | 9/11/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.